Atrium Therapeutics, Inc. RNA
6.68 USD +0.25 (+3.89%)
As ofNov 17, 2026, 1:41 PM EST
6.45 Day range 6.95
6.36 52-week range 16.77
- YTD
- -54.71%
- 1 year
- -54.71%
News
benzinga.com Atrium Therapeutics Q3 EPS $(0.25) Beats $(1.37) Estimate, Sales $15.321M Beat $666.667K Estimate Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(1.37) by 81.75 percent. This is a 80.31 percent increase over losses of…
prnewswire.com Atrium Therapeutics Reports Third Quarter 2026 Financial Results -- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features…benzinga.com Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndromeThe nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2…
benzinga.com HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Atrium Therapeutics (NASDAQ:RNA) with a Buy and lowers the price target from $25 to $20.
benzinga.com Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027 Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first…
benzinga.com This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for CleanSpark, Constellation Energy and Atrium; Outperform for Kardigan; Neutral for Northwest Natural.benzinga.com Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $15.
benzinga.com Shareholder Yakira Capital Urges Atrium Therapeutics To Explore Strategic Sale Or Partnerships, Citing 44% Stock Decline, $50M Dilutive Financing Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a…
